Current Pharmaceutical Design
Volume 25, 46 Issues, 2019
ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)
This journal supports open access
ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)
This journal supports open access
Contents
Current Pharmaceutical Design, Volume 20 - Number 24
Editorial
Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
, 20(24): 3863 - 3874Elena Galvani, Francesca Toffalorio, Godefridus J. Peters, Tommaso De Pas and Elisa Giovannetti
DOI: 10.2174/13816128113196660756
PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
, 20(24): 3875 - 3882Matteo Giaj Levra, Ken Andre Olaussen, Silvia Novello and Jean-Charles Soria
DOI: 10.2174/13816128113196660765
Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
, 20(24): 3883 - 3893Luciano Wannesson, Santiago Viteri, Carlota Costa, Niki Karachaliou, Miguel Angel Molina-Vila and Rafael Rosell
DOI: 10.2174/13816128113196660758
Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC
, 20(24): 3894 - 3900Paolo Maione, Antonio Rossi, Marianna Bareschino, Paola Claudia Sacco, Clorinda Schettino, Francesca Casaluce, Assunta Sgambato and Cesare Gridelli
DOI: 10.2174/13816128113196660764
Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
, 20(24): 3901 - 3913Massimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, Gennaro Daniele, Pasqualina Giordano, Raffaele Costanzo, Claudia Sandomenico, Agnese Montanino, Gaetano Rocco and Francesco Perrone
DOI: 10.2174/13816128113196660762
MET and ALK as Targets for the Treatment of NSCLC
, 20(24): 3914 - 3932Capelletti M, Gelsomino F. and Tiseo M.
DOI: 10.2174/13816128113196660760
Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
, 20(24): 3933 - 3943Sheila Piva, Monica Ganzinelli, Marina Chiara Garassino, Elisa Caiola, Gabriella Farina, Massimo Broggini and Mirko Marabese
DOI: 10.2174/13816128113196660761
Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
, 20(24): 3944 - 3957Ludovica Ciuffreda, Ursula Cesta Incani, Linda S. Steelman, Stephen L. Abrams, Italia Falcone, Anais Del Curatolo, William H. Chappell, Richard A. Franklin, Sabrina Vari, Francesco Cognetti, James A. McCubrey and Michele Milella
DOI: 10.2174/13816128113196660763
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
, 20(24): 3958 - 3972Sara Pilotto, Maria Bonomi, Francesco Massari, Michele Milella, Ludovica Ciuffreda, Matteo Brunelli, Matteo Fassan, Marco Chilosi, Aldo Scarpa, Giampaolo Tortora and Emilio Bria
DOI: 10.2174/13816128113196660757
Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
, 20(24): 3973 - 3981Marcello Maugeri-Sacca, Monica Bartucci, Alfredo Pagliuca, Michele Patrizii, Michele Signore and Ruggero De Maria
DOI: 10.2174/13816128113196660759
MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises
, 20(24): 3982 - 3990D. Cortinovis, V. Monica, F Pietrantonio, G.L. Ceresoli, C.M. La Spina and L. Wannesson
DOI: 10.2174/13816128113196660755
   |
Editor-in-Chief
William A. Banks
Seattle VA Puget Sound Health Care System
Room 810C, Building 1
1660 S. Columbian Way
Seattle, WA 98108
USA
Seattle VA Puget Sound Health Care System
Room 810C, Building 1
1660 S. Columbian Way
Seattle, WA 98108
USA
About the Journal
For Authors
For Librarians & Readers
Journal History
Current Pharmaceutical Design was introduced in 1995 with the assistance of Dr. William A. Banks, who is the current Editor-in-Chief serving since 1995.
Webmaster Contact: info@benthamscience.net